Embedded Files
Tumor-Specific Universal Cancer Drugs
Tumor-Specific Universal Cancer Drugs that do Not Bind to Normal Tissues
Our proprietary invention “Tumor-Specific-Targeting-Platform” specifically target tumor, do Not bind to normal tissues, zero off-target. It binds to most human cancers, and does not binds to any normal human tissues. It can be used to develop ADC drugs, CAR-T, radio-drugs, cancer vaccines, and tumor-imaging agents to treat most cancer types. It can reduce drug toxic side-effects and cancer therapy-induced patient death, complex diseases, lifespan shortening, and secondary cancers. Also, due to its low dose-limiting toxicity (DLT); it can maximize drug dose in patients and maximize therapy efficacy.
__ In comparison, current anticancer drugs and CAR-T targeting to EGFR, CEACAM5, Nectin-4, CD19, CD20, CD40, CD44v6, CD47, CD70, CD73, CTLA-4, PD-L1, Caprin-1, Trop2, PSMA, HER2, HER3, PTK7, FRα, DLL3, TIGIT, CLDN18.2, FAP, VEGF, and B7-H3…etc., developing by AbbVie, AstraZeneca, BMS, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, and Roche…etc., show strong binding to normal tissues. Thus, these drugs and CAR-T can cause patient organ failure and speed death！ Also, due to their high dose-limiting toxicities (DLTs); they have to limit drug dose in patients, thus these drugs have low theraoy efficacies.
Many failed/discontinued clinical trials of ADC drugs targeting to CD47, TIGIT, DLL3, HER2, HER3, PTK7, FRα, CD44v6, PD-L1, EGFR, Nectin4, CD70, Trop2, PSMA, CEACAM5, CD73, VEGF, and B7-H3 were reported due to severe toxicity, off-target toxicity, and limited efficacy in patients.
There is news that anti-CLDN18.2 ADC clinical trial showed to prolong the survival days for 2 to 8 months (not cured) of CLDN18.2-positive gastric cancer patients, but did not report the data of adverse drug reaction in the patients.
CLDN18.2 protein expression in normal tissues only in normal lungs, gallbladder, and stomach, these organs are not like liver, spleen, or kidney that if damaged will directly cause patient death. Thus, although anti-CLDN18.2 ADC can pass clinical trials, the lungs, gallbladder, and stomach of the patients might be severely damaged.
We welcome cooperation to save patients.
Invention-2: Tumor Signal Transduction-Liquid Biopsy
Universal early stage cancer screening to cut tumors away, making cancer cured easily.
Real-time therapy resistance detection. Guiding correct therapy. Preventing patients from taking ineffective drugs.
Guiding precision dosing. Reducing drug side-effects in cancer therapy.
Detecting early cancer relapse to timely treat it.
Real-time cancer action detection.
Clinical Trials
Competitive Analysis
Contact: jiangmwd@gmail.com
Page updated
Google Sites
Report abuse